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Clinical PerspectiveWhat Is New?We identified a gene set that appears specific for terminal aneurysm wall weakening and ultimate rupture. Identified genes converge at an accentuated HIF‐1α signaling.What Are the Clinical Implications?These findings may help to direct future research to establish better risk prediction tools and possibly provide novel targets for medical therapy aimed at stabilizing growing abdominal aortic aneurysms.

Introduction {#jah32739-sec-0008}
============

Rupture of abdominal aortic aneurysms (AAAs) represents a common cause of mortality in developed countries, predominantly in white men over 65 years of age with a history of smoking and/or hypertension.[1](#jah32739-bib-0001){ref-type="ref"} The definitive therapy for AAAs is surgery or stent placement, which is performed when the risk of rupture outweighs the risk of intervention. Current clinical risk assessment fully relies on diameter. According to prevailing guidelines, AAA repair should be performed when AAAs expand to ≥55 mm.[2](#jah32739-bib-0002){ref-type="ref"} Although the majority of ruptures occur at sizes far beyond 55 mm, rupture does occur at AAAs smaller than 55 mm. Therefore, more individualized risk prediction is urgently needed in order to prevent premature ruptures and unnecessary invasive repair, especially because treatment is associated with reasonable perioperative morbidity and high costs. Today the exact mechanisms underlying AAA progression and ultimate rupture are unknown. Although AAA growth and rupture can be the consequence of continuous and progressive wall destabilization, functional evidence from imaging studies and molecular studies implies AAA rupture is a process that is (partially) distinct from AAA growth.[3](#jah32739-bib-0003){ref-type="ref"} Serial monitoring of the biological activity of AAA would be valuable both in identifying high‐risk patients and in prompting earlier therapy to prevent rupture while sparing patients at low risk from morbid procedures. Results from positron emission tomography (PET) scans performed with ^18^F‐fluorodeoxyglucose show that functional AAA wall imaging is feasible.[4](#jah32739-bib-0004){ref-type="ref"} Yet, the nature of the relevant changes, and consequently their applicability as a risk prediction tool, has recently been scrutinized because conclusions from PET studies vary widely.[5](#jah32739-bib-0005){ref-type="ref"} Because the reliability of conventional tracers for monitoring the biological activity of AAA is under controversial debate, there is a need for new more specific molecular targets and tracers for AAA rupture risk prediction. Therefore, it is essential to identify the molecular changes preceding or associated with AAA rupture.

Our study aimed at identifying genes and pathways related to AAA rupture. Using microarray analyses, we undertook an unbiased bioinformatics approach to elaborate pathways potentially associated with AAA rupture. Candidate genes were validated in an independent cohort by quantitative polymerase chain reaction (PCR), and their correlation to diameter was tested. Results of this analysis showed a strong association for selective upregulation of genes involved with the processes of angiogenesis and adipogenesis during end‐stage AAA disease. Histological validation confirmed the functional activation of these processes in fibroblasts but not in inflammatory cells. Upstream, most upregulated pathways converged at activation of HIF‐1α signaling. The data herein provide a reference framework for the development of diagnostic and possibly medical strategies specifically targeted at preventing AAA rupture.

Methods {#jah32739-sec-0009}
=======

Study Cohorts {#jah32739-sec-0010}
-------------

AAA specimens were obtained from a total of 84 patients undergoing open AAA repair. Full‐thickness AAA biopsies were obtained from the anterior aneurysm sac and snap frozen in liquid nitrogen. Specimens were collected and stored at −80°C until assayed. Utilization of human vascular tissues was approved by the ethics committee of the Medical Faculty Dresden University (EK 316122008), and the protocol conformed to ethical guidelines of the Declaration of Helsinki. For patients with AAA, risk factors were recorded on enrollment. Dyslipidemia, hypertension, and diabetes mellitus were defined by a history of diagnosis or treatment of hyperlipidemia, hypertension, or diabetes mellitus. Coronary artery disease was defined by a history of myocardial infarction, angina, or treatment. Smoking was defined by history as past or current (ever) smoker, and never smoker. Maximum infrarenal aortic diameter was assessed in patients with AAA from axial computed tomography angiography images or duplex sonography. Maximum AAA diameter was recorded in millimeters.

Human primary cells (endothelial cells, smooth muscle cells, adipocytes isolated from adipose tissue, and adventitial fibroblasts) from nondiabetic, nonsmoking patients were obtained, and experimental procedures were performed within the framework of the nonprofit Human Tissue and Cell Research Foundation.[6](#jah32739-bib-0006){ref-type="ref"} Written informed consent was obtained from all subjects.

RNA, Reverse Transcription, and Quantitative PCRs {#jah32739-sec-0011}
-------------------------------------------------

Total RNA was extracted from 48 AAA biopsies using the TRIzol reagent (Sigma, St. Louis, MO) and was purified using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions before transcriptome analyses. RNA from 28 AAA biopsies used for array analysis (elective AAA \[eAAA\]: n=20, and ruptured AAA \[rAAA\]: n=8) were also included for validation experiments with accordingly extracted RNA from additional stable (n=26) and ruptured AAA samples (n=10). RNA from blood cells (peripheral blood mononuclear cells, CD14‐, CD19‐, CD‐3, CD4‐, CD8‐positive cells, and regulatory T‐cells was obtained by Clontech \[Mountain View, CA; pool of 2 to 3 donors\]) as well as from human primary cells was isolated using TRIzol reagent. Reverse transcription and quantitative real‐time PCR were performed as previously described.[7](#jah32739-bib-0007){ref-type="ref"} Primers and probes for investigated genes (*HILPDA*,*ANGPTL4*,*SLC39A14*,*LOX*,*ADAMTS9*,*SRPX2*,*STC1*,*GFPT2*,*FCGBP*,*GAL3ST4*,*CCL4L1*, and *RAB7B*) are given in Table [1](#jah32739-tbl-0001){ref-type="table-wrap"}. Absolute copies were determined using plasmid standard curves and were normalized to micrograms of RNA. All quantitative PCR experiments were performed in quadruplicate.

###### 

Primers and Probes Used for Validation of Differential Gene Expression Levels With Quantitative Real‐Time Polymerase Chain Reaction

  Gene         Primer/Probe                              Sequence                      Length (bp)
  ------------ ----------------------------------------- ----------------------------- -------------
  *ADAMTS9*    5′‐primer                                 5′‐CCAAGCCAACATCTATGCAG‐3′    102
  3′‐primer    5′‐GCTGGTATCCCTGTCCACAA‐3′                                              
  Probe        5′F‐TTGTCAGCAGCCGGAATGTGCATCCTGGC‐3′T                                   
  *ANGPTL4*    5′‐primer                                 5′‐GTGGACCCTGAGGTCCTTC‐3′     82
  3′‐primer    5′‐CCACCTTGTGGAAGAGTTGC‐3′                                              
  Probe        5′F‐AGACACAACTCAAGGCTCAGAACAGCAGGAT‐3′T                                 
  *HILPDA*     5′‐primer                                 5′‐CTACAGCCGGCGATCCA‐3′       114
  3′‐primer    5′‐AGAAACAGAGCTGCCTTCTCCTT‐3′                                           
  Probe        5′F‐CGGCTGTTCCCCCGGAGGG‐3′T                                             
  *GFPT2*      5′‐primer                                 5′‐GGCTGTTCTCCGAGGATATG‐3′    123
  3′‐primer    5′‐TGGGACAGGTCTGGAATCA‐3′                                               
  Probe        5′F‐CCAAGTCTGTAACTGTGGAATGAGGCTGAGA‐3′T                                 
  *LOX*        5′‐primer                                 5′‐CGGATACGGCACTGGCTACTT‐3′   73
  3′‐primer    5′‐GGACGCCTGGATGTAGTAGGG‐3′                                             
  Probe        5′F‐ACGGTCTCCCAGACCTGGTGGCC‐3′T                                         
  *SLC39A14*   5′‐primer                                 5′‐ACGCAGAACGCAGACAGTT‐3′     96
  3′‐primer    5′‐CATAAGCCAAGCAGGGTCAG‐3′                                              
  Probe        5′F‐ACCATGAAGCTGCTGCTGCTGCACC‐3′T                                       
  *SRPX2*      5′‐primer                                 5′‐GGCATGTGACCATCATTGAA‐3′    118
  3′‐primer    5′‐CGAGTGAGGCGCTGAAAT‐3′                                                
  Probe        5′F‐AGCAACAGCTGTCAGCCAACATCATCGA‐3′T                                    
  *STC1*       5′‐primer                                 5′‐GTGGCGGCTCAAAACTCA‐3′      121
  3′‐primer    5′‐AGATGTCATACATCCCATCTGTGT‐3′                                          
  Probe        5′F‐TGCTCTACAGGTCGGCTGCGGG‐3′T                                          
  *CCL4L1*     5′‐primer                                 5′‐CTTCCTCGCAACTTTGTGGT‐3′    96
  3′‐primer    5′‐GCAGACTTGCTTGCCTCTTT‐3′                                              
  Probe        5′F‐TCTGCTCCCAGCCAGCTGTGGTATTC‐3′T                                      
  *FCGBP*      5′‐primer                                 5′‐CAACCACAGCCTGACACTGA‐3′    97
  3′‐primer    5′‐GTGCAGGAGCGAGTCCAG‐3′                                                
  Probe        5′F‐AAGCTACAGGTCGACGGCGTGTTCGT‐3′T                                      
  *GAL3ST4*    5′‐primer                                 5′‐TCTTGGGGAAAGTTGAGCTG‐3′    120
  3′‐primer    5′‐GCAGATTTTTGCCTCTGTCA‐3′                                              
  Probe        5′F‐CGATTTCCCTTGCTGCTCCCCTTGT‐3′T                                       
  *RAB7B*      5′‐primer                                 5′‐TCCAAGGCTGGAATCTTTTTC‐3′   96
  3′‐primer    5′‐CCATTGAAGACCCTGAGAGG‐3′                                              
  Probe        5′F‐AGGCAGCACAGACAGGGCCTAGCCT‐3′T                                       
  *ACTB*       5′‐primer                                 5′‐ CCTGGCACCCAGCACAAT ‐3′    70
  3′‐primer    5′‐ GCCGATCCACACGGAGTACTT ‐3′                                           
  Probe        5′F‐ATCAAGATCATTGCTCCTCCTGAGCGCA ‐3′T                                   

Probes were labeled: 5′FAMRA (5′F‐) and 3′TAMRA (‐3′T). bp indicates base pairs.

Microarray Analysis {#jah32739-sec-0012}
-------------------

Transcriptome‐wide expression analysis was performed using the Illumina (San Diego, CA) HumanHT‐12 v4 Expression BeadChip platform as previously described.[8](#jah32739-bib-0008){ref-type="ref"} Background correction and quantile normalization were performed by the limma package[9](#jah32739-bib-0009){ref-type="ref"} used in R version 3.2. Differential expression was calculated using empirical Bayes statistics and corrected for multiples testing as implemented in the limma package. The intersection of differentially expressed genes (\|log~2~ fold change~‐~\[FC\]\| ≥1.5, adjusted *P*\<0.05) in both analysis of eAAA versus rAAA samples and intermediate‐ (iAAA) versus large‐AAA (lAAA) samples were identified. Upstream regulators were analyzed using the Ingenuity Pathway Analysis (<http://www.ingenuity.com>) considering transcripts with an absolute log~2~FC ≥1 as differentially expressed. Gene expression data have been deposited at Gene Expression Omnibus under the GEO Accession number [GSE98278](GSE98278).

Histology and Immunohistochemistry {#jah32739-sec-0013}
----------------------------------

Tissue samples were obtained from the maximally dilated region (aneurysm sac) of 9 patients with different AAA diameters (≤55 mm, n=3; \>70 mm; n=3; rAAA, n=3) and divided in 2 parts. One half was immediately snap‐frozen in liquid nitrogen and stored at −80°C for later analysis. The other half was fixed in 4% formalin for 12 hours and decalcified. Afterward the latter segments were paraffin embedded, and 4‐μm sections were processed into slices.

Paraffin sections of full‐thickness human AAA tissue were stained with hematoxylin and eosin.

For immunostaining, aortic sections were rehydrated in PBS, permeabilized for 15 minutes in 0.5% Triton X100 PBS, and blocked for 30 minutes in PBS containing 1% BSA, 2% donkey serum, and 0.3% Triton X100 PBS (blocking buffer) at room temperature. Sections were probed with primary antibodies diluted in blocking buffer 1:100 at 4°C overnight. The following primary antibodies were used: ANGPTL4 (PA5‐26216, ThermoFischer Scientific, Waltham, MA), HILPDA (ABIN2175788, antikoerper‐online), SRPX2 (ab91584, Abcam, Cambridge, UK), LOX (ab31238, Abcam), FCGBP (ab121202, Abcam). After incubation, sections were washed 3 times with PBS and incubated with appropriate conjugated secondary antibodies and then diluted in blocking buffer 1:500 at room temperature for 2 hours. Nuclei were stained with Hoechst 33342 (Sigma Aldrich, St. Louis, MO) and SMA using the ImmPress HRP Anti‐Rabbit and Anti‐Mouse Ig Polymere Detection System (Vector Laboratories, Burlingame, CA) during secondary antibody incubation. Afterward, sections were washed 3 times with PBS, mounted with Fluorescence Mounting Medium (Dako, Santa Clara, CA) and kept at 4°C for imaging. Antibodies against HIF‐1α (ab8366, Abcam), vimentin (M7020, Dako), and CD31 (JC70A, Dako) were diluted 1:1000 in 5% BSA. The 4plus Biotinylated Universal Goat link kit (Biocare Medical, Pacheco, CA) in combination with 4plus streptavidin AP label was used as secondary antibody for Ferangi Blue and Vulcan Red visualizations in combination with Mayer hematoxylin (Merck Millipore, Billerica, MA).

Stained slides were scanned at ×400 magnification with a Philips IntelliSite Fast Scanner (Philips, Eindhoven, The Netherlands), and representative sections are shown in figures 5, 6, and 8.

Histological/Morphometric Analysis {#jah32739-sec-0014}
----------------------------------

Microvessel density of the medial‐adventitial border zone was quantified by light microscopy. Wall sections were Ulex‐stained and then scanned. Vessel lumen areas were marked, and the relative vessel area per full wall section was estimated with ImageJ.

Statistical Analysis {#jah32739-sec-0015}
--------------------

Demographic patient data are presented as mean±standard deviation or as absolute and relative frequency. Comparison of categorical demographic data between patient cohorts was performed using the Fisher exact test. A Mann‐Whitney U test was performed to identify differences in continuous variables and expression levels of selected genes between eAAA and rAAA in the validation cohort. The Spearman rank correlation coefficient was determined to detect associations for gene expression levels and related phenotypes. Multiple comparisons of gene expression levels in different tissues were performed using the Kruskal‐Wallis test with adjustment for multiple comparison. A *P*\<0.05 was considered statistically significant. Differences in gene expression levels between samples are given as log~2~FC. Statistical analyses were performed using R software (R Foundation for Statistical Computing, Vienna, Austria) and GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA).

Results {#jah32739-sec-0016}
=======

Identification of Transcripts Associated With AAA Progression and Rupture {#jah32739-sec-0017}
-------------------------------------------------------------------------

To identify genes and pathways associated with AAA progression and rupture, we harvested tissue from the aneurysm sacs of 48 patients undergoing open elective and emergency AAA repair. Patient characteristics are summarized in Table [2](#jah32739-tbl-0002){ref-type="table-wrap"}. We performed 2 analyses in the same set of patients to identify genes that (1) associate with rupture and (2) associate with both progression and rupture of AAA (Figure [1](#jah32739-fig-0001){ref-type="fig"}). First, we compared the gene expression profiles of patients undergoing elective repair (n=31) with those undergoing emergency repair due to AAA rupture (n=17). Groups were similar with respect to age, sex, hypertension, dyslipidemia, coronary artery disease, diabetes mellitus, and history of smoking (Table [2](#jah32739-tbl-0002){ref-type="table-wrap"}). The groups differed significantly regarding maximum aortic diameter (62.3±12.1 mm versus 77.0±14.7 mm; *P*\<0.001) and male sex (97% versus 77%; *P*\<0.05). Exploration of differential gene expression (\|log~2~FC\| ≥1.5‐fold, adjusted *P*\<0.05) between the eAAA and rAAA groups identified 68 differentially expressed transcripts (Tables [3](#jah32739-tbl-0003){ref-type="table-wrap"} and [4](#jah32739-tbl-0004){ref-type="table-wrap"}). Because size is the strongest known factor to predispose for both AAA progression and rupture, we aimed at identifying genes that are associated with a strong propensity for rupture. Hence, in a second analysis we compared patients with iAAA (≤55 mm, n=15, small rupture risk) and those with lAAA (\>70 mm, n=16, ruptured and eAAA with high rupture risk---risk defined on basis of the diameter) in the same cohort. The mean diameters in these groups were 54.1±1.8 mm versus 84.1±12.6 mm (*P*\<0.0001). Groups were similar with regard to common cardiovascular risk factors. In this analysis we identified 32 transcripts that were differentially expressed between iAAA and lAAA (\|log~2~Fc\| ≥1.5‐fold, adjusted *P*\<0.05; Tables [5](#jah32739-tbl-0005){ref-type="table-wrap"} and [6](#jah32739-tbl-0006){ref-type="table-wrap"}). We observed a considerable overlap between the differentially expressed gene sets in the eAAA versus rAAA analysis and the second iAAA versus lAAA analysis. A total of 14 transcripts were differentially expressed (\|log~2~Fc\| ≥1.5‐fold, adjusted *P*\<0.05) in both analyses (Figure [1](#jah32739-fig-0001){ref-type="fig"}). We considered these transcripts the most promising candidates for risk assessment. The 14 transcripts represent 12 individual genes (*Fc fragment binding protein* \[*FCGBP*\] shows 2 significant transcripts, and no corresponding gene was found for the downregulated transcript *LOC728835*). Transcripts that were upregulated (ie, higher in rAAA than in lAAA) correspond to the following genes (Table [7](#jah32739-tbl-0007){ref-type="table-wrap"}): *a disintegrin and metalloproteinase with thrombospondin type 1 motif 9 (ADAMTS9)*,*angiopoietin‐like 4 (ANGPTL4)*,*hypoxia‐inducible lipid droplet associated protein (HILPDA or C7orf68)*,*lysyl‐oxidase (LOX)*,*solute carrier family 39 family A 14 (SLC39A14 or ZIP14)*,*sushi repeat protein X‐linked 2 (SRPX2), stanniocalcin‐1 (STC1)*, and *glutamine‐fructose‐6‐phosphate transaminase 2 (GFPT2)*. Downregulated genes (lower in rAAA than in lAAA) were *C‐C chemokine ligand 4‐like 1 (CCL4L1)*,*Fc fragment binding protein (FCGBP)*,*Gal‐3‐sulfontransferase 4 (GAL3ST4),* and *ras‐related protein Rab‐7b (RAB7B)*.

###### 

Patient Characteristics

  Characteristic      Identification Cohort (Array)   Validation Cohort (qPCR)                                                                      
  ------------------- ------------------------------- -------------------------- -------- ---------- ----------- ---------- ----------- ----------- ----------
  N                   31                              17                                  15         16                     46          18          
  Age, y              69.5±7.2                        73.5±11.3                  ns       67.7±7.4   72.3±9.2    ns         68.9±7.1    73.4±11.9   0.0296
  Male sex            97%                             77%                        0.0467   93%        88%         ns         96%         78%         0.0477
  BMI                 27.2±3.3                        26.1±4.6                   ns       28.3±3.3   26.4±3.8    ns         27.9±4.2    26.2±4.4    ns
  Diameter, mm        62.3±12.1                       77.0±14.7                  0.0002   54.1±1.8   84.1±12.6   \<0.0001   62.7±13.3   79.8±16.0   \<0.0001
  CAD                 58.1%                           41.2%                      ns       46.7%      43.8%       ns         52.2%       44.4%       ns
  Hypertension        93.5%                           88.2%                      ns       86.7%      93.8%       ns         93.5%       94.4%       ns
  Diabetes mellitus   32.3%                           23.5%                      ns       26.7%      31.3%       ns         37.0%       22.2%       ns
  Dyslipidemia        77.4%                           82.3%                      ns       86.7%      81.3%       ns         76.1%       82.4%       ns
  (Ever) smoking      58.1%                           58.8%                      ns       33.3%      68.8%       ns         66.7%       70.6%       ns

For patients with AAA, risk factors were recorded. Dyslipidemia, hypertension, and diabetes mellitus were defined by a history of diagnosis or treatment of hyperlipidemia, hypertension, or diabetes mellitus. Coronary artery disease (CAD) was defined by a history of myocardial infarction, angina, or treatment. Smoking was defined by history as past or current (ever) smoker, and never smoker. Maximum infrarenal aortic diameter was assessed in patients with AAA from axial computed tomography angiography images or duplex sonography. Maximum AAA diameter was recorded in millimeters. Nominal variables are presented as percentages; continuous variables are presented as mean±standard deviation. Continuous variables were compared using the Mann‐Whitney U test; nominal variables were compared using the Fisher exact test. Associations of expression levels and variables listed were tested using the Spearman rank correlation. The *P*‐value was corrected for multiple testing using the Bonferroni correction. No significant correlations (*P*\<0.05) were identified for age, sex, BMI, CAD, hypertension, diabetes mellitus, dyslipidemia, and smoking. Thus, gene expression levels were not adjusted for these phenotypes. Correlation of gene expression level and diameter of aneurysms was expected due to the experimental design. AAA indicates abdominal aortic aneurysm; BMI, body mass index; eAAA, stable---treated electively---abdominal aortic aneurysm; iAAA, intermediate size (≤55 mm) abdominal aortic aneurysm; lAAA, large size (\>70 mm) abdominal aortic aneurysm); ns, not significant; qPCR, quantitative polymerase chain reaction; rAAA, ruptured abdominal aortic aneurysm.

![Study design. A, Two array analyses were performed in the identification cohort: ruptured (rAAA) vs stable and intermediate (≤55 mm) vs large (\>70 mm) size AAA. The Venn diagram above depicts the overlap among the different groups in the identification cohort. The Venn diagrams underneath show the overlap among the identified differentially expressed transcripts of the 2 analyses. An independent validation cohort was used to validate the overlapping candidate genes from the array analyses with quantitative real‐time PCR. B, Volcano plot of differentially expressed transcripts for eAAA vs rAAA array analysis. C, Volcano plot of differentially expressed transcripts for intermediate vs large AAA array analysis (colored dots, \|log~2~ FC\| ≥1.5, adjusted *P*\<0.05). AAA indicates abdominal aortic aneurysm; eAAA, elective AAA; iAAA, intermediate AAA; lAAA, large AAA; qRT‐PCR, quantitative real‐time polymerase chain reaction; rAAA, ruptured AAA.](JAH3-6-e006798-g001){#jah32739-fig-0001}

###### 

Differentially Expressed Upregulated Transcripts (log~2~FC \>1.5 and Adjusted *P*\<0.05) by Comparison of Samples Taken From the Aneurysmatic Wall During Open Repair From Patients With Stable/Elective Surgery Versus From Patients With Ruptured/Emergency Repair

  Illumina Number   Symbol       log~2~FC   Adjusted *P* Value
  ----------------- ------------ ---------- --------------------
  ILMN_1659990      *HILPDA*     2.6149     0.0000
  ILMN_2386444      *ANGPTL4*    2.3552     0.0000
  ILMN_1775170      *MT1X*       2.3523     0.0000
  ILMN_1780349      *TPR*        2.1645     0.0070
  ILMN_1805543      *ADAMTS9*    2.1005     0.0001
  ILMN_1685714      *INHBB*      2.0515     0.0000
  ILMN_1764629      *SLC39A14*   2.0280     0.0000
  ILMN_1695880      *LOX*        2.0091     0.0002
  ILMN_1685608      *NPTX2*      1.9739     0.0001
  ILMN_1707727      *ANGPTL4*    1.9397     0.0000
  ILMN_1720623      *SYTL3*      1.8774     0.0000
  ILMN_1676213      *SRPX2*      1.8692     0.0001
  ILMN_1661895      *PI15*       1.7970     0.0004
  ILMN_1715401      *MT1G*       1.7884     0.0001
  ILMN_1661695      *IRAK3*      1.7567     0.0000
  ILMN_2375879      *VEGFA*      1.7518     0.0003
  ILMN_3221432      *PRG4*       1.7495     0.0036
  ILMN_2136089      *MTE*        1.7278     0.0000
  ILMN_1674376      *ANGPTL4*    1.6973     0.0001
  ILMN_2074477      *GPR4*       1.6824     0.0000
  ILMN_2189027      *LIPG*       1.6812     0.0000
  ILMN_1758164      *STC1*       1.6694     0.0019
  ILMN_1752932      *MPZL2*      1.6678     0.0000
  ILMN_1782938      *SLC16A10*   1.6468     0.0086
  ILMN_2305407      *ZBTB16*     1.6300     0.0032
  ILMN_2127298      *F2RL3*      1.6259     0.0000
  ILMN_1738725      *LIF*        1.6241     0.0031
  ILMN_1772131      *IL1R2*      1.6025     0.0005
  ILMN_1691884      *STC2*       1.5867     0.0000
  ILMN_1696048      *C13orf33*   1.5651     0.0027
  ILMN_1657435      *MT1M*       1.5415     0.0024
  ILMN_1709674      *GFPT2*      1.5399     0.0076
  ILMN_2071446      *PI15*       1.5324     0.0006
  ILMN_1657234      *CCL20*      1.5317     0.0028
  ILMN_2331231      *TNFRSF6B*   1.5251     0.0002
  ILMN_1803824      *ZDHHC9*     1.5093     0.0000

###### 

Differentially Expressed Downregulated Transcripts (log~2~FC \<−1.5 and Adjusted *P*\<0.05) by Comparison of Samples Taken From the Aneurysmatic Wall During Open Repair From Patients With Stable/Elective Surgery Versus From Patients With Ruptured/Emergency Repair

  Illumina Number   Symbol        log~2~FC   Adjusted *P* Value
  ----------------- ------------- ---------- --------------------
  ILMN_1801307      *TNFSF10*     −1.5078    0.0005
  ILMN_1808590      *GUCY1A3*     −1.5107    0.0053
  ILMN_1761833      *SLC40A1*     −1.5231    0.0019
  ILMN_1771688      *RAB7B*       −1.5508    0.0002
  ILMN_2175317      *CYP4X1*      −1.5595    0.0016
  ILMN_2347798      *IFI6*        −1.5607    0.0003
  ILMN_1743199      *EGR2*        −1.5952    0.0007
  ILMN_1799467      *SAMD9L*      −1.6022    0.0000
  ILMN_3235832      *LOC728835*   −1.6131    0.0023
  ILMN_2218856      *CCL3L1*      −1.6166    0.0029
  ILMN_1693452      *GAL3ST4*     −1.6258    0.0001
  ILMN_1716276      *CCL4L2*      −1.6633    0.0012
  ILMN_1655821      *CAPG*        −1.6853    0.0051
  ILMN_1739393      *SELE*        −1.7106    0.0045
  ILMN_1796316      *MMP9*        −1.7138    0.0061
  ILMN_1718984      *FCGBP*       −1.7323    0.0040
  ILMN_2100209      *CCL4L1*      −1.7473    0.0015
  ILMN_3243185      *RERGL*       −1.7496    0.0050
  ILMN_2374449      *SPP1*        −1.7563    0.0075
  ILMN_2053103      *SLC40A1*     −1.7820    0.0004
  ILMN_2105573      *CCL3L3*      −1.8140    0.0002
  ILMN_1739428      *IFIT2*       −1.8652    0.0001
  ILMN_1815205      *LYZ*         −1.8863    0.0031
  ILMN_2165753      *HLA‐A29.1*   −1.8869    0.0344
  ILMN_2073758      *MMP12*       −1.9865    0.0185
  ILMN_1671509      *CCL3*        −2.0419    0.0002
  ILMN_1723912      *IFI44L*      −2.0946    0.0000
  ILMN_2302757      *FCGBP*       −2.0977    0.0042
  ILMN_1775501      *IL1B*        −2.1044    0.0001
  ILMN_1747355      *CCL3L1*      −2.1117    0.0002
  ILMN_1707695      *IFIT1*       −2.1544    0.0000
  ILMN_1772964      *CCL8*        −2.1997    0.0000

###### 

Differentially Expressed Upregulated Transcripts (log~2~FC \>1.5 and Adjusted *P*\<0.05) by Comparison of Samples Taken From the Aneurysmatic Wall During Open Repair From Patients With Intermediate Sized AAA Versus From Patients With Large AAA

  Illumina Number   Symbol       log~2~FC   Adjusted *P* Value
  ----------------- ------------ ---------- --------------------
  ILMN_1659990      *HILPDA*     2.1272     0.0034
  ILMN_2386444      *ANGPTL4*    1.9538     0.0057
  ILMN_2206722      *FER1L4*     1.9440     0.0054
  ILMN_1695880      *LOX*        1.9348     0.0078
  ILMN_2139970      *ALDH1A3*    1.8483     0.0079
  ILMN_1754716      *HAS1*       1.7569     0.0076
  ILMN_2193233      *MGC29506*   1.7282     0.0438
  ILMN_1805543      *ADAMTS9*    1.6960     0.0114
  ILMN_1709674      *GFPT2*      1.6569     0.0183
  ILMN_1797009      *F3*         1.5984     0.0003
  ILMN_1758164      *STC1*       1.5849     0.0093
  ILMN_1676213      *SRPX2*      1.5808     0.0083
  ILMN_1776967      *LRRC50*     1.5796     0.0081
  ILMN_1720373      *SLC7A5*     1.5527     0.0250
  ILMN_1807439      *ALDH1A3*    1.5430     0.0477
  ILMN_1764629      *SLC39A14*   1.5400     0.0018
  ILMN_1787345      *FKBP11*     1.5327     0.0004
  ILMN_2129572      *F3*         1.5145     0.0087

Intermediate size is ≤55 mm; large is \>70 mm. AAA indicates abdominal aortic aneurysm.

###### 

Differentially Expressed Downregulated Transcripts (log~2~FC \<−1.5 and Adjusted *P*\<0.05) by Comparison of Samples Taken From the Aneurysmatic Wall During Open Repair From Patients With Intermediate Sized AAA Versus From Patients With Large AAA

  Illumina Number   Symbol        log~2~FC   Adjusted *P* Value
  ----------------- ------------- ---------- --------------------
  ILMN_1771688      *RAB7B*       −1.5108    0.0067
  ILMN_1774874      *IL1RN*       −1.5184    0.0320
  ILMN_1693452      *GAL3ST4*     −1.5337    0.0039
  ILMN_1744968      *KCNAB1*      −1.5365    0.0402
  ILMN_3235832      *LOC728835*   −1.5392    0.0372
  ILMN_2088437      *CX3CR1*      −1.5744    0.0019
  ILMN_2100209      *CCL4L1*      −1.5949    0.0305
  ILMN_1688423      *FCER1A*      −1.7426    0.0000
  ILMN_1789007      *APOC1*       −1.7483    0.0261
  ILMN_1746888      *PCOLCE2*     −1.7866    0.0005
  ILMN_1712475      *HS3ST2*      −1.8449    0.0157
  ILMN_1718984      *FCGBP*       −2.3486    0.0009
  ILMN_2302757      *FCGBP*       −2.4189    0.0054
  ILMN_1715169      *HLA‐DRB1*    −2.8815    0.0317

Intermediate size is ≤55 mm; large is \>70 mm. AAA indicates abdominal aortic aneurysm.

###### 

Identified Candidate Genes and Their Change in Expression Levels

  Gene         Study Cohort (Array)   Validation Cohort (qPCR Replication)                                                   
  ------------ ---------------------- -------------------------------------- -------- -------- -------- ---------- --------- --------
  *HILPDA*     2.615                  \<0.0001                               2.128    0.0034   2.025    \<0.0001   0.3753    0.0019
  *ANGPTL4*    2.355                  \<0.0001                               1.954    0.0057   1.765    \<0.0001   0.3176    0.0094
  *ADAMTS9*    2.100                  \<0.0001                               1.696    0.0114   1.143    0.0006     0.1799    ns
  *SLC39A14*   2.028                  \<0.0001                               1.54     0.0018   0.901    ns         0.1319    ns
  *LOX*        2.009                  0.0002                                 1.935    0.0078   1.035    0.0001     0.3336    0.0062
  *SRPX2*      1.869                  \<0.0001                               1.581    0.0083   1.306    0.0029     0.3903    0.0012
  *STC1*       1.669                  0.0019                                 1.585    0.0093   0.640    0.0393     0.07098   ns
  *GFPT2*      1.540                  0.008                                  1.657    0.0183   1.085    0.0227     0.2243    ns
  *RAB7B*      −1.551                 0.0002                                 −1.511   0.0067   −0.439   ns         −0.0548   ns
  *GAL3ST*     −1.626                 \<0.0001                               −1.534   0.0039   −2.403   0.0170     −0.181    ns
  *FCGBP*      −1.732                 0.0040                                 −2.349   0.0009   −0.642   0.0033     −0.2672   0.0301
  *CCL4L1*     −1.747                 0.0015                                 −1.595   0.0305   −0.799   0.0490     −0.1      ns

Overlapping genes differentially expressed in the identification cohort (array) with \|log~2~FC\| ≥1.5 and adjusted *P*\<0.05. Assessed changes in gene expression levels normalized to β‐actin detected by qPCR and correlation of gene expression levels with AAA diameter in the validation cohort. ns indicates not significant.

AAA indicates abdominal aortic aneurysm; eAAA, stable, elective AAA; iAAA, intermediate sized AAA; lAAA, large AAA; qPCR, quantitative polymerase chain reaction; rAAA, ruptured AAA.

Validation of Candidate Genes and Correlation With AAA Size {#jah32739-sec-0018}
-----------------------------------------------------------

We next aimed to replicate our findings in a second, independent cohort consisting of 64 patients undergoing elective (eAAA, n=46) and emergency (rAAA, n=18) open AAA repair. The eAAA and rAAA patients in this cohort were different with regard to age (68.9±7.1 years versus 73.4±11.9 years, *P*\<0.05), sex (96% versus 78% male sex; *P*\<0.05), and AAA diameter (62.7±13.3 mm \[eAAA\] versus 79.8±16.0 mm \[rAAA\], *P*\<0.0001). Groups were similar with respect to body mass index, coronary artery disease, hypertension, diabetes mellitus, dyslipidemia, and history of smoking (Table [2](#jah32739-tbl-0002){ref-type="table-wrap"}). We performed qualitative real‐time PCR analyses for the 12 genes, and absolute copies were normalized to expression of the housekeeping gene *β‐actin* (Table [7](#jah32739-tbl-0007){ref-type="table-wrap"}). We confirmed differential expression for 10 genes, but *SLC39A14* and *RAB7B* were not validated, possibly due to technical means (low copy numbers).

Correlation between gene expression levels and diameter was observed for 5 genes (Table [7](#jah32739-tbl-0007){ref-type="table-wrap"} & Figure [2](#jah32739-fig-0002){ref-type="fig"}), indicating that these genes were associated with terminal AAA progression and AAA rupture (terminal progression‐associated genes). The other 5 candidates (*ADAMTS9*,*STC1*,*GFPT2*,*GAL3ST4*,*CCL4L1*) did not show an association with diameter and were therefore considered to be exclusively related to rupture (rupture only--associated genes; Figure [3](#jah32739-fig-0003){ref-type="fig"}). From a diagnostic and therapeutic point of view, the changes preceding AAA rupture are obviously of the highest interest. Therefore, we focused on these 5 terminal progression--associated genes (*ANGPTL4*,*HILPDA*,*LOX*,*SRPX2*, and *FCGBP*) for subsequent analyses.

![Gene expression levels of 5 genes are associated with AAA rupture and diameter. Normalized gene expression levels (validation cohort) of differentially expressed genes in rAAA, which also showed significant correlation to AAA diameter (terminal progression--associated genes). Gene expression levels were normalized to β‐actin. Data are demonstrated as mean±SEM, and Mann‐Whitney U test was performed to identify differences in expression levels of selected genes between eAAA and rAAA. Spearman rank correlation coefficient (*r*) was determined to detect associations for gene expression levels and AAA diameter. AAA indicates abdominal aortic aneurysm; eAAA, elective AAA; rAAA, ruptured AAA.](JAH3-6-e006798-g002){#jah32739-fig-0002}

![Results of the validation for candidate genes without correlation to AAA diameter. A, ADAMTS9, GFPT2, and STC1 were validated for higher expression levels in rAAA. B, Decreased gene expression for rAAA was also demonstrated for CCL4L1 and GAL3ST4 in the validation cohort, but their gene expression levels showed no significant correlation with diameter (rupture only--associated genes). Differential gene expression levels for SLC39A14 and RAB7B could not be reproduced. Gene expression levels were normalized to β‐actin. Data are illustrated as mean±SEM, and Mann‐Whitney U test was performed to identify differences in expression levels of selected genes between eAAA and rAAA. Spearman rank correlation coefficient (*r*) was determined to detect associations for gene expression levels and AAA diameter. AAA indicates abdominal aortic aneurysm; eAAA, elective AAA; rAAA, ruptured AAA.](JAH3-6-e006798-g003){#jah32739-fig-0003}

To further investigate if the selected 5 genes constituted specific markers for abdominal aneurysms but not for aneurysms at other sites of the vasculature or for atherosclerotic vascular disease, we quantified their expression in RNA isolated from degenerative and dissected thoracic, infrarenal aortic, and popliteal aneurysms (Figure [4](#jah32739-fig-0004){ref-type="fig"}A) as well as from atherosclerotic plaques. For *ANGPTL4*,*HILPDA*,*LOX*, and *SRPX2*, which are upregulated during AAA progression and rupture, highest expression was found in AAA but not in degenerative and dissected thoracic or popliteal aneurysms. Low expression was found in atherosclerotic plaques of the carotid and common femoral arteries, indicating that the gene expression signature was specific for AAA but not for other dilative or atherosclerotic lesions. For *FCGBP*, we observed lower expression in AAA compared to atherosclerotic plaques, which is consistent with the observed downregulation in the gene expression data.

![Gene expression signature is unique for AAA disease and originates from mesenchymal cells. A, Identified upregulated candidate genes exclusively associated with AAA, and gene expression is distinct from other dilative vascular disorders (eg, popliteal aneurysm, aortic dissection) as well as atherosclerotic changes. Downregulated genes were expressed at low levels in AAA and showed higher expression levels in other vascular pathologies. B, For almost all upregulated genes (except HILPDA) higher expression levels were detected in mesenchymal cell types (fibroblasts, adipocytes, and smooth muscle cells) than in inflammatory cells. Downregulated candidate genes showed highest expression levels in peripheral blood mononuclear cells (PBMC). Quadruplicate measurements per condition. Data are given as mean±SEM. Kruskal‐Wallis test was performed for multiple comparison analyses. Adjusted *P*\<0.05 was considered significant (\**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001). AAA indicates abdominal aortic aneurysm; CFA, common femoral artery; diss. TAA, dissected thoracic aortic aneurysm; EC, endothelial cells; ICA, internal carotid artery; popl., popliteal; SMC, smooth muscle cells; TAA, thoracic aortic aneurysm.](JAH3-6-e006798-g004){#jah32739-fig-0004}

Terminal Progression--Associated Genes Are Highly Expressed in Mesenchymal Cells Within AAA Walls {#jah32739-sec-0019}
-------------------------------------------------------------------------------------------------

To dissect which cells within AAA were the main sources of gene expression, we performed a profiling of blood cells (peripheral blood mononuclear cells, CD14‐positive monocytes, B‐cells \[CD19\], CD3‐, CD4‐, CD8‐positive T‐cells, and regulatory T‐cells) that eventually might invade the vascular periphery and AAA wall and of vascular cells, such as endothelial cells, adventitial fibroblasts, adipocytes, and smooth muscle cells. *ANGPTL4*,*HILPDA*,*LOX*, and *SRPX2* revealed high expression in fibroblasts and smooth muscle cells, and only *HILPDA* was more highly expressed in blood cells (Figure [4](#jah32739-fig-0004){ref-type="fig"}B). This cell profiling suggests that upregulated candidate genes are mainly expressed by cells of mesenchymal origin and not inflammatory cells invading from the blood. These findings indicate that terminal AAA weakening is more likely to be characterized by fibrotic changes in tissue composition than inflammatory alterations.

Immunohistochemical analysis of these 5 candidate genes confirmed the presence of the proteins they encode in the aneurysm wall (Figure [5](#jah32739-fig-0005){ref-type="fig"}). ANGPTL4, HILPDA, SRPX2, and LOX staining was localized in pericytes of microvessels in the medial‐adventitial border zone. Staining for SRPX2 was diffuse in the media and colocalized to adipocytes in the adventitia. Also, ANGPTL4 staining was observed in adipocytes of the adventitia. For ANGPTL4, SRPX2, and LOX, diffuse staining was witnessed in tertiary lymphoid follicles of the medial layer of tissue cross sections from rAAAs. Sparse FCGBP staining was localized near microvessels in the media of eAAAs and was absent in rAAAs.

![Results of the immunohistochemistry. Staining for protein products of our candidate genes confirmed presence in the aneurysmatic wall. ANGPTL4, HILPDA,SRPX2, and LOX are localized in pericytes of microvessels in the medial‐adventitial border zone. Staining for SRPX2 is diffuse in the media and also observed in adipocytes of the adventitia. Demonstrated are representative sections from a 55‐mm stable abdominal aortic aneurysm.](JAH3-6-e006798-g005){#jah32739-fig-0005}

Molecular Effector Pathways of AAA‐Marker Genes {#jah32739-sec-0020}
-----------------------------------------------

Literature research revealed that the 5 AAA candidate genes were associated with following processes: angiogenesis (*ANGPTL4*,[10](#jah32739-bib-0010){ref-type="ref"} *LOX*,[11](#jah32739-bib-0011){ref-type="ref"} *SRPX2* [12](#jah32739-bib-0012){ref-type="ref"}), adipogenesis (*ANGPTL4*,[13](#jah32739-bib-0013){ref-type="ref"} *HILPDA*,[14](#jah32739-bib-0014){ref-type="ref"} *LOX* [15](#jah32739-bib-0015){ref-type="ref"}), and epithelial‐mesenchymal transition (*FCGBP*,[16](#jah32739-bib-0016){ref-type="ref"} *LOX*,[17](#jah32739-bib-0017){ref-type="ref"} *SRPX2* [18](#jah32739-bib-0018){ref-type="ref"}). An increase in medial neovascularization and fatty degeneration has already been reported for specimens from end‐stage AAA disease.[3](#jah32739-bib-0003){ref-type="ref"}, [19](#jah32739-bib-0019){ref-type="ref"} We therefore performed histological quantification of microvascular density in rAAA versus eAAA in a subset (n=5 in each group) of our study cohort. This analysis revealed significantly enhanced microvessel density (*P*\<0.05; Figure [6](#jah32739-fig-0006){ref-type="fig"}) likely caused by increased neovascularization. To dissect the underlying molecular mechanism, we next performed an upstream regulator analysis of differentially expressed genes from the eAAA versus rAAA (n=308) and iAAA versus lAAA analyses (n=246) using the Ingenuity Pathway Analysis software (Qiagen, Hilden, Germany). This predicted HIF‐1α signaling to be 1 of the most significantly upregulated networks with an activation *z*‐score of 4.329 and an overlap *P* value of 2.74×10^−22^ (Table [8](#jah32739-tbl-0008){ref-type="table-wrap"}). Exploration of the HIF‐1α network with Ingenuity Pathway Analysis shows clear activation of the HIF‐1α network in rAAA (Figure [7](#jah32739-fig-0007){ref-type="fig"}). These observations suggest progressive activation of the HIF‐1α signaling pathway in advanced AAA disease. Immunohistochemical evaluation of HIF‐1α in AAA showed localized, prominent staining in large nucleated cells in the infiltrates surrounding the vasa vasora in the medial‐adventitial border zone and in the adventitial adipocytes. Dual positivity of these cells for HIF‐1α and CD31 as well as vimentin and CD31, suggests that, in infiltrates, HIF‐1α activation associates with cells undergoing endothelial‐to‐mesenchymal transition (EndoMT; Figure [8](#jah32739-fig-0008){ref-type="fig"}) and that end‐stage AAA disease involves EndoMT.

![Increased neovascularization in rAAA. A, Results of the determination of microvessel density between (B) stable (eAAA) and (C) ruptured AAA (rAAA) samples (n=5/group); \**P*\<0.05. Arrows indicate microvessels in the media‐adventitia border zone of aneurysmatic walls. Data are demonstrated as mean±SEM, and Mann‐Whitney U test was performed to identify differences of the percentage of vasa vasorum. AAA indicates abdominal aortic aneurysm; eAAA, elective AAA; rAAA, ruptured AAA.](JAH3-6-e006798-g006){#jah32739-fig-0006}

###### 

Results of the Ingenuity Upstream Regulator Analysis of Both Array Data Sets

  Upstream Regulators              *z*‐Score eAAA vs rAAA   *z*‐Score iAAA vs lAAA
  -------------------------------- ------------------------ ------------------------
  NUPR1                            4.278                    5.815
  HIF‐1α                           4.329                    3.775
  TRIM24                           4.422                    3.043
  VEGF                             3.267                    4.162
  HGF                              3.235                    3.645
  5‐N‐Ethylcarboxamido adenosine   2.836                    3.449
  Prostaglandin E~2~               3.093                    2.765
  SOCS1                            2.881                    2.711
  SCARB1                           2.630                    2.770
  ACKR2                            3.051                    2.333
  Mibolerone                       2.435                    2.795
  TGFB1                            2.352                    2.862
  PTGER4                           2.856                    2.152
  Deferoxamine                     2.266                    2.687
  Aspirin                          2.642                    2.303
  HDAC4                            2.563                    2.360
  DNase2                           2.606                    2.213
  Dexamethasone                    2.235                    2.555
  CTLA4                            2.414                    2.191
  ERN1                             2.558                    2.025
  TGFB2                            2.159                    2.402
  STAR                             2.236                    2.236
  Prednisolone                     2.362                    2.012
  Triamcinolone acetonide          2.333                    2.026
  5‐Azacytidine                    2.076                    2.237
  Sodium arsenite                  2.089                    2.173
  FOSB                             2.201                    2.005
  Phosphate                        2.156                    2.045
  Nelfinavir                       2.000                    2.177
  HDL                              2.138                    2.005

Demonstrated are all activated regulators with activation *z*‐score \>2 in both analysis for the identification cohort. Transcripts correlated with rAAA and lAAA (\|log~2~FC\| ≥1.0 and adjusted *P*\<0.05; n=308 and n=246, respectively; Ingenuity Pathway Analysis) were included in the analysis. AAA indicates abdominal aortic aneurysm; ACKR2, atypical chemokine receptor 2; CTLA4, cytotoxic T‐lymphocyte associated protein 4; DNase2, deoxyribonuclease 2; ERN1, endoplasmic reticulum to nucleus signaling 1; HDAC4, histone deacetylase 4; HDL, high density lipoprotein; HGF, hepatocyte growth factor; HIF‐1a, hypoxia inducible factor 1 alpha; lAAA, large AAA; NUPR1, nuclear protein 1; PTGER4, prostaglandin E receptor 4; rAAA, ruptured AAA; SCARB1, scavenger receptor class B member 1; SOCS1, suppressor of cytokine signaling 1; STAR, steroidogenic acute regulatory protein; TGFB1, transforming growth factor beta 1; TGFB2, transforming growth factor beta 2; TRIM24, tripartite motif containing 24; VEGF, vascular endothelial growth factor.

![HIF‐1α strongly associates with differentially expressed genes in rAAA. Results from the Ingenuity pathway analysis (stable vs ruptured AAAs) for the activated upstream regulator HIF‐1α (activation *z*‐score 4.329 and an overlap *P* value of 2.74×10^−22^) showing the significantly up‐ (red) and downregulated (green) genes and their localization in the cell. Figure ©2000‐2016 by Qiagen (Hilden, Germany). Reproduced with permission.](JAH3-6-e006798-g007){#jah32739-fig-0007}

![HIF‐1α expression is detected in cells undergoing EndoMT. Results of HIF‐1α and CD31 staining (CD31 \[blue\], HIF‐1α \[red\] double staining): (A) overview (scale bar=500 μm). HIF‐1α staining is particularly prominent in the well‐vascularized areas (B) but minimally expressed in the avascular areas (C). D, Perivascular CD‐31/HIF‐1α double‐positive mononuclear cells (arrows) suggest HIF‐1α expression in cells undergoing EndoMT. This finding is supported by a CD31 (blue) and vimentin (red) double staining: (E) overview (scale bar=500 μm). F, Perivascular (vasa vasorum) CD31/vimentin double‐positive mononuclear cells (arrows) are found in the media‐adventitia border (scale bar=50 μm). G, Again, minimal expression is observed in the avascular areas of the intima‐media zone (scale bar=50 μm). EndoMT indicates endothelial‐to‐mesenchymal transition.](JAH3-6-e006798-g008){#jah32739-fig-0008}

All in all the above data show a terminal progression--associated gene signature that appears unique to terminal AAA dilatation and rupture. Both at the regulation of their expression and functionally (hypoxia/angiogenesis), the selected upregulated factors converge at the level of the canonical HIF‐1α signaling pathway.

Discussion {#jah32739-sec-0021}
==========

Even though multiple etiological, genetic, and environmental factors contributing to AAA have been identified in the past decade, the mechanisms leading to terminal aorta weakening and ultimate rupture are still incompletely understood. Gene expression array analyses provide a comprehensive, global view of disease‐related genes, as well as of activated or inactivated pathways.

There have been a few earlier investigations with different study designs using gene expression array analyses from AAA patients,[20](#jah32739-bib-0020){ref-type="ref"}, [21](#jah32739-bib-0021){ref-type="ref"}, [22](#jah32739-bib-0022){ref-type="ref"}, [23](#jah32739-bib-0023){ref-type="ref"}, [24](#jah32739-bib-0024){ref-type="ref"}, [25](#jah32739-bib-0025){ref-type="ref"} but this is the first study using whole genome microarrays to compare relative mRNA expression patterns between stable and ruptured AAAs in order to identify processes associated with AAA progression and rupture. With our approach we were able to identified and validate 2 gene sets. The first gene set relates to AAA growth and rupture (*terminal progression--associated genes*). A second set of 5 candidate genes (*STC1*,*ADAMTS9*,*GFPT2*,*GAL3ST4*, and *CCL4L1*) showed no significant correlation of gene expression level and AAA diameter and thus seems to be exclusively associated with rupture (*rupture only--associated genes*).

It is well known that AAA disease has a very strong chronic inflammatory component. We earlier reported about changes in the lymphocyte subpopulation in small versus large AAAs.[22](#jah32739-bib-0022){ref-type="ref"} How far these changes contribute to or associate with AAA rupture is uncertain. Except for *CCL4L1,* none of the identified top candidate genes has been reported to be a typical inflammatory response gene.[26](#jah32739-bib-0026){ref-type="ref"} Functionally both the terminal progression and rupture‐associated candidate genes clustered with adipogenesis and angiogenesis, processes that appear prominently involved in AAA disease.[3](#jah32739-bib-0003){ref-type="ref"}, [27](#jah32739-bib-0027){ref-type="ref"}

With respect to adipogenesis, we observed an adipogenic signature in the terminal progression--associated AAA candidate set (*HILPDA*,[14](#jah32739-bib-0014){ref-type="ref"} *ANGPTL4,* [13](#jah32739-bib-0013){ref-type="ref"} and *LOX* [15](#jah32739-bib-0015){ref-type="ref"}), and in the rupture only--associated candidate set (*ADAMTS9* [28](#jah32739-bib-0028){ref-type="ref"}). This observation coincides with the findings from a histological reevaluation of AAA disease that attempted to identify culprit mechanisms beyond inflammation and proteases.[19](#jah32739-bib-0019){ref-type="ref"} Results from this evaluation identified fatty degeneration as a so far overlooked process in AAA disease.

More specifically, 3 of the 5 terminal progression-- and 2 of the rupture only--associated candidate genes relate to the process of angiogenesis. ANGPTL4, a matricellular protein, has been shown to promote angiogenesis through integrin binding and STAT3 signaling.[10](#jah32739-bib-0010){ref-type="ref"}, [29](#jah32739-bib-0029){ref-type="ref"} The chondroitin sulfate proteoglycan SRPX2 binds to urokinase plasminogen activator receptor in a ligand‐receptor interaction and is involved in the early phase of endothelial remodeling during angiogenesis.[12](#jah32739-bib-0012){ref-type="ref"} It has been demonstrated that SRPX2 regulates endothelial cell migration and tube formation in vascular endothelial cells.[30](#jah32739-bib-0030){ref-type="ref"} LOX, a copper‐containing monoamine oxidase, has been shown to be critically involved in tumor angiogenesis by promoting cell migration and tube formation.[11](#jah32739-bib-0011){ref-type="ref"} STC1 has been shown to promote angiogenic sprouting in human umbilical vein endothelial cells via vascular endothelial growth factor/vascular endothelial growth factor receptor 2 and angiopoietin signaling pathways.[31](#jah32739-bib-0031){ref-type="ref"} ADAMTS9 acts as an antiangiogenic metalloprotease and is expressed by microvascular endothelial cells.[32](#jah32739-bib-0032){ref-type="ref"} The increased neovascularization that we observed in the medial layer of large and ruptured AAA samples suggested that the observed proangiogenic signature is functional. Yet, whether increased angiogenesis promotes rupture (transversing microvessels may weaken the wall strength) or whether the signature is secondary to physical (hypoxia) and/or molecular changes (inflammation) forestalling rupture is unclear and cannot be addressed in this observational study.

Both processes and almost all candidate genes converge at the master regulator HIF‐1α, which was identified through Ingenuity upstream regulator analysis, suggesting that HIF‐1α may drive the molecular (and functional) fingerprint of terminal aneurysm weakening. HIF‐1α is centrally involved in the cellular responses to oxygen tension. Under normal circumstances, the *HIF‐1α* gene is constitutively expressed in low levels and in normoxic circumstances is rapidly cleared through ubiquination. Hypoxia stabilizes HIF‐1α, thus inhibiting protein degradation and resulting in HIF‐1α accumulation. Alternative (normoxic) HIF‐1α accumulation and signaling have been described to merely reflect upregulation of HIF‐1α gene expression.[33](#jah32739-bib-0033){ref-type="ref"}

In the aneurysm wall, conditions such as mural thrombus, aortic wall thickening, and massive inflammation may create a hypoxic milieu. Yet, AAA is also characterized by excess angiogenesis and an increased vessel density theoretically compensating for the impaired oxygen delivery and demand, and consequently, increased HIF‐1α signaling presumably reflects nonclassical activation through oxygen‐independent regulators of HIF‐1α activity. In nonhypoxic conditions, growth factors, cytokines, and other signaling molecules are able to accumulate HIF‐1α protein in cells.[33](#jah32739-bib-0033){ref-type="ref"} One possible mechanism perpetuating HIF‐1α in AAA is a positive feedback loop between HIF‐1α activation and the candidate gene *LOX*. Classically LOX catalyzes cross‐linking of collagens and elastin in the extracellular matrix, thereby regulating tissue tensile strength. Yet, LOX has also been shown to activate the PI3K‐Akt signaling pathway, thereby upregulating HIF‐1α protein synthesis. In fact, there is compelling evidence that LOX and HIF‐1α act in synergy and that HIF‐1α and LOX are mutually involved in the cellular adaptation to stress.[34](#jah32739-bib-0034){ref-type="ref"}

In our study histological analysis of the aneurysm wall showed abundant HIF‐1α expression in multiple cell types of the aneurysm wall. A remarkable observation was the abundant expression of HIF‐1α in clusters of cells in the tertiary follicles of the aneurysm wall. Double staining experiments indicated that these HIF‐1α--positive clusters of cells stain positive for CD31. Although CD31 is a classical endothelial cell marker, it also identifies cells undergoing EndoMT.[35](#jah32739-bib-0035){ref-type="ref"} EndoMT is a process in which epithelial and endothelial cells lose polarity, detach from their neighboring cells, and gain migratory and invasive properties in order to become mesenchymal stem cells.[36](#jah32739-bib-0036){ref-type="ref"}, [37](#jah32739-bib-0037){ref-type="ref"} EndoMT has been implicated as major driver of tissue fibrosis,[38](#jah32739-bib-0038){ref-type="ref"}, [39](#jah32739-bib-0039){ref-type="ref"} and for the vascular system EndoMT is believed to be the primary contributor to cardiac fibrosis after myocardial infarction.[40](#jah32739-bib-0040){ref-type="ref"} Thus, it can not be excluded that a parallel mechanism is involved in AAA disease.

Notably, there is compelling evidence that HIF‐1α drives the epithelial‐mesenchymal transition (EMT).[41](#jah32739-bib-0041){ref-type="ref"} Again, 3 of the 5 terminal progression-- and 2 of the rupture only--associated candidate genes relate to EMT. It has recently been shown that FCGBP expression is decreased in gallbladder carcinoma and is an independent marker for disease progression and prognosis.[16](#jah32739-bib-0016){ref-type="ref"} The pathophysiological role of LOX during EMT has been studied in aggressive thyroid, colon, and breast tumors.[17](#jah32739-bib-0017){ref-type="ref"} SRPX2 has also been linked to EMT. In glioblastoma SRPX2 facilitates metastasis by enhancing the EMT process via the MAPK signaling pathway.[18](#jah32739-bib-0018){ref-type="ref"} Reportedly the candidate genes *STC‐1* and *CCL4* may also mediate EMT, yet mechanistic insight is missing.[42](#jah32739-bib-0042){ref-type="ref"}, [43](#jah32739-bib-0043){ref-type="ref"}

Together, using a very conservative approach to identify genes with rigorous correction for multiple testing, we identified 2 sets of genes that all fall within a theoretical framework of (impaired) tissue remodeling including angiogenesis, adipogenesis, HIF‐1 activation, and possibly EndoMT. Remarkably, candidate genes do not explicitly associate with presumed culprit processes such as inflammation and proteases, which may, rather, be important in the initiation phase of AAA disease. On the contrary, our data suggest that in the terminal phase of the disease preceding the rupture of AAA expressed genes associate with impaired healing responses. It came to our attention that this may explain failure of medical strategies.[44](#jah32739-bib-0044){ref-type="ref"}

Overall, the identified genes and processes may provide opportunities for improved risk stratification, and our results could be helpful in the search for novel and more effective PET tracers to improve AAA rupture risk stratification. Recently, Shi et al showed increased angiogenesis in calcium phosphate--induced AAAs in mice by PET scanning with ^64^Cu‐labeled anti‐CD105 antibody Fab fragment.[45](#jah32739-bib-0045){ref-type="ref"} With regard to our results, this seems a very promising approach to determine rupture risk in AAA patients in the future.

Because we present results from an observational study, conclusions are based on a bioinformatics approach and histological validation. An in vivo model mimicking end‐stage AAA disease is urgently missing, and as a result we are currently unable to test whether the identified candidates are modulators or merely bystanders of AAA disease and rupture.

Conclusions {#jah32739-sec-0022}
===========

In conclusion, this study examined the global gene expression profile of different sized AAAs as well as stable and ruptured AAAs. We were able to identify gene expression profiles unique for end‐stage AAA disease and identified candidate genes related to processes involved in fibrosis. AAA progression toward rupture is associated with increased angiogenesis in the media and adventitia of the aortic wall. Several genes related to angiogenesis, adipogenesis, and EMT are overexpressed in large and ruptured AAAs. Some of these genes are directly related to HIF‐1α, which seems to be pivotal for AAA progression toward rupture. The exact mechanisms behind HIF‐1α--driven AAA weakening still remain to be further explored, but we recognized an increase in EndoMT and positive HIF‐1α and vimentin staining in CD31^+^ myofibroblasts. Novel PET tracers for imaging processes characteristic of end‐stage AAA disease, such as angiogenesis, are promising tools for a better AAA rupture risk stratification and should be further investigated. Considering our findings and recent results from AAA models in mice,[46](#jah32739-bib-0046){ref-type="ref"}, [47](#jah32739-bib-0047){ref-type="ref"} we believe that pharmacological HIF‐1α inhibition seems a promising medical therapy for patients with stable AAAs.
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